keyword
MENU ▼
Read by QxMD icon Read
search

EGFR

keyword
https://www.readbyqxmd.com/read/29161357/nivolumab-in-non-small-cell-lung-cancer-with-egfr-mutation
#1
H Yoshida, Y H Kim, H Ozasa, H Nagai, Y Sakamori, T Tsuji, T Nomizo, Y Yasuda, T Funazo, T Hirai
No abstract text is available yet for this article.
November 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29161295/cardiac-and-renal-dysfunction-is-associated-with-progressive-hearing-loss-in-patients-with-fabry-disease
#2
Maria Köping, Wafaa Shehata-Dieler, Mario Cebulla, Kristen Rak, Daniel Oder, Jonas Müntze, Peter Nordbeck, Christoph Wanner, Rudolf Hagen, Sebastian Schraven
BACKGROUND: Fabry disease (FD) is an X-linked recessive hereditary lysosomal storage disorder which results in the accumulation of globotriaosylceramid (Gb3) in tissues of kidney and heart as well as central and peripheral nervous system. Besides prominent renal and cardiac organ involvement, cochlear symptoms like high-frequency hearing loss and tinnitus are frequently found with yet no comprehensive data available in the literature. OBJECTIVE: To examine hearing loss in patients with FD depending on cardiac and renal function...
2017: PloS One
https://www.readbyqxmd.com/read/29160908/connective-tissue-growth-factor-induces-renal-fibrosis-via-epidermal-growth-factor-receptor-activation
#3
Sandra Rayego-Mateos, José Luis Morgado-Pascual, Raúl R Rodrigues-Diez, Raquel Rodrigues-Diez, Lucas Falke, Sergio Mezzano, Alberto Ortiz, Jesús Egido, Roel Goldschmeding, Marta Ruiz-Ortega
Connective tissue growth factor (CCN2/CTGF) is a matricellular protein overexpressed in progressive human renal diseases, mainly in fibrotic areas. In vitro studies have demonstrated that CCN2 regulates production of extracellular matrix (ECM) proteins and epithelial mesenchymal transition (EMT), and therefore could contribute to renal fibrosis. CCN2 blockade ameliorates experimental renal damage, including diminution of ECM accumulation. We have described that CCN2 and its C-terminal degradation product CCN2(IV), bind to epidermal growth factor receptor (EGFR) to modulate renal inflammation...
November 21, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/29160717/reprogramming-tumor-associated-macrophages-to-reverse-egfr-t790m-resistance-by-dual-targeting-codelivery-of-gefitinib-vorinostat
#4
Huige Peng, Binfan Chen, Wei Huang, Yubo Tang, Yifan Jiang, Wenyuan Zhang, Yongzhuo Huang
Gefitinib is a first-line therapy in the EGFR-mutated nonsmall cell lung cancer (NSCLC). However, the development of drug resistance is almost unavoidable, thus leading to an unsustainable regimen. EGFR(T790M) mutation is the major cause responsible for the molecular-targeting therapy failure in NSCLC. Although the recently approved osimertinib is effective for the EGFR(T790M)-positive NSCLC, the osimertinib-resistant EGFR mutation is rapidly developed, too. In this study, we proposed a tumor-associated macrophage (TAM) reprogramming strategy for overcoming the EGFR(T790M)-associated drug resistance via a dual-targeting codelivery system of gefitinib/vorinostat that acted on both TAM with overexpression of mannose receptors and the HER-2 positive NSCLC cells...
November 21, 2017: Nano Letters
https://www.readbyqxmd.com/read/29160688/a-novel-real-time-proximity-assay-for-characterizing-multiple-receptor-interactions-on-living-cells
#5
Sina Bondza, Hanna Björkelund, Marika Nestor, Karl Andersson, Jos Buijs
Cellular receptor activity is often controlled through complex mechanisms involving interactions with multiple molecules, which can be soluble ligands and/or other cell surface molecules. In this study, we combine a fluorescence based technology for real-time interaction analysis with fluorescence quenching to create a novel time resolved proximity assay to study protein-receptor interactions on living cells. This assay extracts the binding kinetics and affinity for two proteins if they bind in proximity on the cell surface...
November 21, 2017: Analytical Chemistry
https://www.readbyqxmd.com/read/29160417/radiotherapy-modulates-expression-of-egfr-ercc1-and-p53-in-cervical-cancer
#6
V H de Almeida, A C de Melo, D D Meira, A C Pires, A Nogueira-Rodrigues, H K Pimenta-Inada, F G Alves, G Moralez, L S Thiago, C G Ferreira, C Sternberg
Cervical cancer is a public health problem and the molecular mechanisms underlying radioresistance are still poorly understood. Here, we evaluated the modulation of key molecules involved in cell proliferation, cell cycle and DNA repair in cervical cancer cell lines (CASKI and C33A) and in malignant tissues biopsied from 10 patients before and after radiotherapy. The expression patterns of epidermal growth factor receptor (EGFR), excision repair cross-complementation group 1 (ERCC1) and p53 were evaluated in cancer cell lines by quantitative PCR and western blotting, and in human malignant tissues by immunohistochemistry...
November 13, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/29160082/cyclic-versus-noncyclic-chelating-scaffold-for-89zr-labeled-zegfr-2377-affibody-bioconjugates-targeting-epidermal-growth-factor-receptor-overexpression
#7
Dominik Summer, Javad Garousi, Maryam Oroujeni, Bogdan Mitran, Ken G Andersson, Anzhelika Vorobyeva, John Löfblom, Anna Orlova, Vladimir Tolmachev, Clemens Decristoforo
Zirconium-89 is an emerging radionuclide for positron emission tomography (PET) especially for biomolecules with slow pharmacokinetics as due to its longer half-life, in comparison to fluorine-18 and gallium-68, imaging at late time points is feasible. Desferrioxamine B (DFO), a linear bifunctional chelator (BFC) is mostly used for this radionuclide so far but shows limitations regarding stability. Our group recently reported on fusarinine C (FSC) with similar zirconium-89 complexing properties but potentially higher stability related to its cyclic structure...
November 21, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29159913/a-small-organic-molecule-blocks-egfr-transport-into-the-nucleus-by-the-non-classical-pathway-resulting-in-repression-of-cancer-invasion
#8
Siyoung Ha, Jangho Jeong, Jiwon Oh, Sangmyung Rhee, Seung Wook Ham
In addition to the traditional epidermal growth factor receptor (EGFR) signaling pathways, nuclear EGFR has been shown to control multiple cellular functions, including cell proliferation and invasion. It has been reported that EGFR is transported into the nucleus after forming a complex with KPNA/KPNB1 or KPNB1. In this study, we have shown that EGFR can interact with both KP and KPNA, but EGF-activated EGFR mostly binds with KPNB1 through the pull-down assay. We also found that a small organic molecule (compound 1), an effective binder of KPNB1, inhibited the interaction between EGFR and KPNB1 in the non-classical transport pathway, but not KPNA...
November 20, 2017: Chembiochem: a European Journal of Chemical Biology
https://www.readbyqxmd.com/read/29159457/ertugliflozin-in-patients-with-stage-3-chronic-kidney-disease-and-type-2-diabetes-mellitus-the-vertis-renal-randomized-study
#9
George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G Terra, James P Mancuso, Zhi Wei Jiang, Gregory Golm, Samuel S Engel, Brett Lauring
INTRODUCTION: Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The safety and efficacy of ertugliflozin were evaluated over 52 weeks in patients with chronic kidney disease (CKD). METHODS: In this double-blind randomized study (NCT01986855), patients with glycated hemoglobin (A1C) 7.0-10.5% and stage 3 CKD [estimated glomerular filtration rate (eGFR) ≥ 30 to < 60 mL/min/1.73 m(2)] who were undergoing treatment with standard diabetes therapy (or therapies) including insulin and/or sulfonylureas were randomized to once-daily ertugliflozin 5 mg, 15 mg, or placebo...
November 20, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29158469/molecular-basis-for-necitumumab-inhibition-of-egfr-variants-associated-with-acquired-cetuximab-resistance
#10
Atrish Bagchi, Jaafar N Haidar, Scott W Eastman, Michal Vieth, Michael Topper, Michelle D Iacolina, Jason M Walker, Amelie Forest, Yang Shen, Ruslan D Novosiadly, Kathryn M Ferguson
Acquired resistance to cetuximab, an antibody that targets the epidermal growth factor receptor (EGFR), impacts clinical benefit in head and neck, and colorectal cancers (CRC). One of the mechanisms of resistance to cetuximab is the acquisition of mutations that map to the cetuximab epitope on EGFR and prevent drug binding. We find that necitumumab, another FDA approved EGFR antibody, can bind to EGFR that harbors the most common cetuximab resistance substitution, S468R (or S492R, depending on the amino acid numbering system)...
November 20, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29158193/egfr-gene-copy-number-by-fish-may-predict-outcome-of-necitumumab-in-squamous-lung-carcinomas-analysis-from-the-squire-study
#11
Carlo Genova, Mark A Socinski, Rebecca R Hozak, Gu Mi, Raffael Kurek, Javad Shahidi, Luis Paz-Ares, Nick Thatcher, Christopher J Rivard, Marileila Varella-Garcia, Fred R Hirsch
INTRODUCTION: Necitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). In the SQUIRE trial, the addition of necitumumab to chemotherapy in squamous cell lung cancer (SCC) significantly improved overall survival (OS) (HR=0.84); in a post-hoc analysis, EGFR copy number gain determined by fluorescence in situ hybridization (FISH) showed a trend towards improved OS (HR=0.70) and progression-free survival (PFS) (HR=0.71) with the addition of necitumumab. We present the analysis of granular EGFR-FISH data from SQUIRE to examine the potential predictive role of high polysomy and gene amplification as both were included in the "FISH-positive" category...
November 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29158123/efficacy-and-safety-of-necitumumab-continuation-therapy-in-the-phase-iii-squire-study-of-patients-with-stage-iv-squamous-non-small-cell-lung-cancer
#12
Tudor Ciuleanu, Mark A Socinski, Coleman Obasaju, Alexander V Luft, Aleksandra Szczesna, Wojciech Szafrański, Rodryg Ramlau, Beatrix Bálint, Olivier Molinier, Henrik Depenbrock, Shivani Nanda, Luis Paz-Ares, Nick Thatcher
INTRODUCTION: In a retrospective analysis of the SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) study, we investigated the efficacy and safety of single-agent necitumumab continuation therapy in patients with stage IV squamous non-small-cell lung cancer and in a subpopulation of patients with epidermal growth factor receptor (EGFR)-expressing tumors. PATIENTS AND METHODS: Patients were randomized 1:1 for ≤ 6 cycles of gemcitabine and cisplatin either with or without necitumumab...
October 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29157829/sulfated-galactans-from-the-red-seaweed-gracilaria-fisheri-exerts-anti-migration-effect-on-cholangiocarcinoma-cells
#13
Thannicha Sae-Lao, Natthanej Luplertlop, Tavan Janvilisri, Rutaiwan Tohtong, David O Bates, Kanokpan Wongprasert
BACKGROUND: Seaweeds have a long history of use in Asian countries as functional foods, medicinal herbs, and the treatment of cancer. Polysaccharides from various seaweeds have shown anti-tumor activity. Cholangiocarcinoma (CCA), often with metastatic disease, is highly prevalent in Thailand as a consequence of liver fluke infection. Recently, we extracted sulfated galactans (SG) from Gracilaria fisheri (G. fisheri), a south east Asian seaweed, and found it exhibited anti-proliferation effect on CCA cells...
December 1, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/29157747/multiplex-proximity-ligation-assay-to-identify-potential-prognostic-biomarkers-for-improved-survival-in-locally-advanced-pancreatic-cancer-patients-treated-with-stereotactic-body-radiation-therapy
#14
Avani D Rao, Yufei Liu, Rie von Eyben, Charles C Hsu, Chen Hu, Lauren M Rosati, Arti Parekh, Kendall Ng, Amy Hacker-Prietz, Lei Zheng, Timothy M Pawlik, Daniel A Laheru, Elizabeth M Jaffee, Matthew J Weiss, Dung T Le, Ralph H Hruban, Ana De Jesus-Acosta, Christopher L Wolfgang, Amol K Narang, Daniel T Chang, Albert C Koong, Joseph M Herman
PURPOSE: To explore seromarker levels for associations with outcomes in locally advanced pancreatic cancer (LAPC) patients who received chemotherapy and stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Serum from LAPC patients in 2 prospective trials of hypofractionated SBRT (5-6.6 Gy × 5) was collected before SBRT. Proximity ligation assay quantified the expression levels of 36 pancreatic cancer-specific candidate seromarkers: Axl, BMP2, CA 125, CA 19-9, CEA, CXCL-1/6/9/10, EGFR, Gas6, Her2, IGF-2, IGFBP-2/3/7, IL-6/6Ra/7/8/12, mesothelin, MMP-1/2/3/7, osteopontin, PDGFRa, PDK1, PF4, RegIV, SPARC, TGF-β, VEGF-A/D, and YKL40...
October 12, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29157562/erk-regulates-mitochondrial-membrane-potential-in-fission-deficient-drosophila-follicle-cells-during-differentiation
#15
Darshika Tomer, Rohan Chippalkatti, Kasturi Mitra, Richa Rikhy
Mitochondrial morphology regulatory proteins interact with signaling pathways involved in differentiation. In Drosophila oogenesis, EGFR signaling regulates mitochondrial fragmentation in posterior follicle cells (PFCs). EGFR driven oocyte patterning and Notch signaling mediated differentiation are abrogated when PFCs are deficient for the mitochondrial fission protein Drp1. It is not known whether fused mitochondrial morphology in drp1 mutant PFCs exerts its effects on these signaling pathways through change in mitochondrial electron transport chain (ETC) activity...
November 17, 2017: Developmental Biology
https://www.readbyqxmd.com/read/29157085/sequential-occurrence-of-small-cell-and-non-small-lung-cancer-in-a-male-patient-is-it-a-transformation
#16
Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin Khan, Hafiz Khan, Susan Smith, Yanis Boumber
Lung cancer is one of the leading causes of cancer-related mortality and is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). We present a patient with epidermal growth factor receptor (EGFR)-mutant-NSCLC who developed metastatic SCLC after initial therapy with second-generation EGFR-tyrosine kinase inhibitor, afatinib. A 65-year-old male non-smoker was diagnosed with adenocarcinoma of the right lung, stage IVA (M1a). Due to tumor positivity for EGFR-Exon 19 deletion, the patient was started on oral afatinib, which resulted in a partial response...
November 20, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29157036/epigallocatechin-3-o-gallate-alleviates-the-malignant-phenotype-in-a-431-epidermoid-and-sk-br-3-breast-cancer-cell-lines
#17
Alexandru Filippi, Tiphanie Picot, Carmen Mariana Aanei, Péter Nagy, János Szöllősi, Lydia Campos, Constanţa Ganea, Maria-Magdalena Mocanu
In this study, we evaluated the effects of epigallocatechin-3-O-gallate (EGCG) in two cancer cell lines, A-431 overexpressing ErbB1 and SK-BR-3, overexpressing ErbB2. EGCG treatment showed dose-dependent collapse of mitochondrial membrane potential (Δψm), increase in reactive oxygen species (ROS) production, changes in nuclear morphology and reduced viability. Flow cytometry data indicated that EGCG partially decreases the phosphorylation of several proteins involved in cell proliferation and survival: pErbB1(Y1173, Y1068), pAkt(S473) and pERK(Y204)...
November 21, 2017: International Journal of Food Sciences and Nutrition
https://www.readbyqxmd.com/read/29157028/enhanced-selective-cellular-uptake-and-cytotoxicity-of-epidermal-growth-factor-conjugated-liposomes-containing-curcumin-on-egfr-overexpressed-pancreatic-cancer-cells
#18
Uyen Minh Le, Amanda Hartman, Gopalakrishna Pillai
Pancreatic cancer is one of the most malignant cancers with a high mortality rate. Some types of pancreatic cancer cells overexpress epidermal growth factor receptor (EGFR), which is a potential target for anticancer agents. In this study, we examined the effect of epidermal growth factor (EGF)-conjugated liposomes containing curcumin (EGF-LP-Cur) on three different EGFR-expressed human pancreatic cancer cell lines, BxPC-3, Panc-1, and Mia Paca-2. We have demonstrated that it is feasible to prepare liposomal vesicles of EGF-LP-Cur and that it is stable in the liquid vehicle at ambient conditions for 3 weeks...
November 20, 2017: Journal of Drug Targeting
https://www.readbyqxmd.com/read/29156842/associations-between-egfr-gene-polymorphisms-and-susceptibility-to-glioma-a-systematic-review-and-meta-analysis-from-gwas-and-case-control-studies
#19
Xiao Yu, Nian Rong Sun, Hai Tao Jang, Shi Wen Guo, Min Xue Lian
The results of genome-wide association studies (GWAS) and case-control studies performed to investigate the associations between epidermal growth factor receptor (EGFR) gene polymorphisms and glioma risk are controversial. The aim of this systematic review and meta-analysis is to determine whether EGFR gene polymorphisms are associated with glioma risk by searching 'PubMed', 'EMBASE', 'Web of Science', 'Cochrane Library' and 'China WeiPu Library' to retrieve studies that investigated associations between EGFR gene polymorphisms and glioma risk...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156817/near-infrared-photothermal-therapy-using-anti-egfr-gold-nanorod-conjugates-for-triple-negative-breast-cancer
#20
Meihua Zhang, Hoe Suk Kim, Tiefeng Jin, Jisu Woo, Yin Ji Piao, Woo Kyung Moon
Current EGFR-targeted therapy for triple negative breast cancer (TNBC) has produced disappointing results. A rational therapeutic strategy to improve EGFR-targeted treatment for TNBC is therefore needed. In this study we evaluated the feasibility of treating TNBC using photoacoustic imaging (PAI)-guided near-infrared photothermal therapy (NIR-PTT) with anti-EGFR-conjugated gold nanorods (anti-EGFR-GN). NIR-PTT combined with anti-EGFR-GN exerted synergistic anti-proliferative and apoptotic actions through upregulation of HSP70 and cleaved caspase-3, downregulation of Ki-67 and EGFR, and inhibition of several intracellular signaling molecules (mTOR, AKT, ERK1/2 and FAK)...
October 17, 2017: Oncotarget
keyword
keyword
2132
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"